The present disclosure provides certain tricyclic compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

##STR00001##

The present disclosure provides certain tricyclic compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

##STR00001##

A chromene compound which can exhibit excellent photochromic properties. The chromene compound is represented by the following formula (1). In the formula, at least one of R.sup.1 or R.sup.2 represents the group having the radical-polymerizable group, wherein the group having a radical-polymerizable group is represented by the following formula (2) (wherein R.sup.10 represents a linear or branched alkylene group having 1 to 10 carbon atoms and l represents an integer of from 0 to 50); and the ring Z that is represented by the following formula (Z) and is spiro-bonded to a carbon atom located at position-13 in the formula (1) is preferably an aliphatic cyclic group that may have a substituent, the group having 3 to 20 carbon atoms for forming the ring together with the carbon atom at the 13-position, or the like.

##STR00001##

A chromene compound which can exhibit excellent photochromic properties. The chromene compound is represented by the following formula (1). In the formula, at least one of R.sup.1 or R.sup.2 represents the group having the radical-polymerizable group, wherein the group having a radical-polymerizable group is represented by the following formula (2) (wherein R.sup.10 represents a linear or branched alkylene group having 1 to 10 carbon atoms and l represents an integer of from 0 to 50); and the ring Z that is represented by the following formula (Z) and is spiro-bonded to a carbon atom located at position-13 in the formula (1) is preferably an aliphatic cyclic group that may have a substituent, the group having 3 to 20 carbon atoms for forming the ring together with the carbon atom at the 13-position, or the like.

##STR00001##

A family of α-glucosidase inhibitors are identified. Exemplary α-glucosidase inhibitors may be obtained from Heterophragma adenophyllum seem. The inhibitors are used to lower blood sugar levels and thus to treat diseases related to or characterized by high blood sugar, such as diabetes.

A family of α-glucosidase inhibitors are identified. Exemplary α-glucosidase inhibitors may be obtained from Heterophragma adenophyllum seem. The inhibitors are used to lower blood sugar levels and thus to treat diseases related to or characterized by high blood sugar, such as diabetes.

A family of α-glucosidase inhibitors are identified. Exemplary α-glucosidase inhibitors may be obtained from Heterophragma adenophyllum seem. The inhibitors are used to lower blood sugar levels and thus to treat diseases related to or characterized by high blood sugar, such as diabetes.

A family of α-glucosidase inhibitors are identified. Exemplary α-glucosidase inhibitors may be obtained from Heterophragma adenophyllum seem. The inhibitors are used to lower blood sugar levels and thus to treat diseases related to or characterized by high blood sugar, such as diabetes.

The present invention relates to the technical field of organic chemical engineering, and in particular to a key intermediate for synthesizing prostaglandin compounds and a preparation method therefor. When applied to the synthesis of prostaglandin compounds, the process flow is simplified, the yield and product purity are improved, the production costs are reduced, and the industrial application is easy.

##STR00001##

The present disclosure concerns a group of cannabinoid compounds defined by formulas (I) to (IV), wherein R.sub.1 is —H or —COOH, for the first time isolated and fully characterized in structure, absolute stereochemistry by the present applicant. Methods of isolation, characterization, stereoselective synthesis, biological activity, pharmaceutical compositions and therapeutic applications of the present compounds as modulators of the cannabinoid CB1 receptor are also object of the disclosure.

##STR00001##